First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Circle Pharma and Verismo feature in coveted sessions.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
